Reply to "Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach".

Autor:	Hui, Wen, Gao, Zhixiang, Zhu, Min, Wu, Huazhang, Cai, Yuanyi
Předmět:	NON-small-cell lung carcinoma COMBINATION drug therapy IMMUNOTHERAPY COST effectiveness
Zdroj:	BMC Cancer; 7/22/2024, Vol. 24 Issue 1, p1-3, 3p
Abstrakt:	In this article, we read with great attention the correspondence by Bullement et al., regarding our published study on cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer. We referred to a few the most important comments from Bullement et al. in our opinion, including proportional hazard (PH) assumption, accelerated failure time (AFT) model, and health utility, and made some explanations. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.